
Equillium Inc (EQ) Stock Forecast & Price Target
Equillium Inc (EQ) Analyst Ratings
Bulls say
Equillium is expected to see significant success with its novel drug EQ504 for the treatment of ulcerative colitis due to its potent targeting of the AhR signaling pathway and its potential as a safer alternative to current treatments. With promising phase 1 and 2 trial plans and increasing interest from investors and potential partnerships, the company's estimated takeout price of $40.14/share reflects its strong potential for growth and success in this market.
Bears say
Equillium is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory disorders, with a primary goal of advancing the drug EQ504 for ulcerative colitis. While the drug has shown promise in clinical trials, competition and potential safety risks must be considered. The company's lack of approved drugs and reliance on a single drug in development also add to the overall risk and uncertainty surrounding Equillium's stock.
This aggregate rating is based on analysts' research of Equillium Inc and is not a guaranteed prediction by Public.com or investment advice.
Equillium Inc (EQ) Analyst Forecast & Price Prediction
Start investing in Equillium Inc (EQ)
Order type
Buy in
Order amount
Est. shares
0 shares